Perlecan is required for the chondrogenic differentiation of synovial mesenchymal cells through regulation of Sox9 gene expression

Journal of Orthopaedic Research

Volumn 35, Issue 4, 2017, Pages 837-846

  Sadatsuki, Ryo ^a   Kaneko, Haruka ^a   Kinoshita, Mayuko ^a   Futami, Ippei ^a   Nonaka, Risa ^a   Culley, Kirsty L ^b   Otero, Miguel ^b   Hada, Shinnosuke ^a   Goldring, Mary B ^b   Yamada, Yoshihiko ^c   Kaneko, Kazuo ^a   Arikawa Hirasawa, Eri ^a   Ishijima, Muneaki ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

chondrogenic differentiation; osteophyte; perlecan; Sox9; synovial mesenchymal cell

Indexed keywords

CELL SURFACE MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 2; OSTEOCALCIN; PERLECAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; PROTEOHEPARAN SULFATE; RUNX2 PROTEIN, MOUSE; SOX9 PROTEIN, MOUSE;

ADIPOGENESIS; ADULT; ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; CARTILAGE MATRIX; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROGENESIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; IN VITRO STUDY; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIAL MESENCHYMAL CELL; SYNOVIOCYTE; ANIMAL; CARTILAGE; CELL CULTURE; CHONDROCYTE; CYTOLOGY; GENE EXPRESSION REGULATION; KNOCKOUT MOUSE; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; SYNOVIUM;

ADIPOGENESIS; ANIMALS; CARTILAGE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHONDROCYTES; CHONDROGENESIS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; GENE EXPRESSION REGULATION; HEPARAN SULFATE PROTEOGLYCANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; OSTEOGENESIS; PPAR GAMMA; SOX9 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE;

EID: 84977100960     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.23318     Document Type: Article

References (40)

1. Felson DT. 2006. Clinical practice. Osteoarthritis of the knee. N Engl J Med 354:841–848.
2. Wieland HA, Michaelis M, Kirschbaum BJ, et al. 2005. Osteoarthritis—an untreatable disease? Nat Rev Drug Discov 4:331–344.
3. van der Kraan PM, van den Berg WB. 2007. Osteophytes: relevance and biology. Osteoarthritis Cartilage 15:237–244.
4. Ishijima M, Suzuki N, Hozumi K, et al. 2012. Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation. Matrix Biol 31:234–245.
5. Karsenty G. 2003. The complexities of skeletal biology. Nature 423:316–318.
6. Kronenberg HM. 2003. Developmental regulation of the growth plate. Nature 423:332–336.
7. Schelbergen RF, de Munter W, van den Bosch MH, et al. 2014. Alarmins S100A8/S100A9 aggravate osteophyte formation in experimental osteoarthritis and predict osteophyte progression in early human symptomatic osteoarthritis. Ann Rheum Dis 2014:2014–205480.
8. van Lent PL, Blom AB, van der Kraan P, et al. 2004. Crucial role of synovial lining macrophages in the promotion of transforming growth factor beta-mediated osteophyte formation. Arthritis Rheum 50:103–111.
9. Arikawa-Hirasawa E, Watanabe H, Takami H, et al. 1999. Perlecan is essential for cartilage and cephalic development. Nat Genet 23:354–358.
10. Dodge GR, Boesler EW, Jimenez SA. 1995. Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells. Lab Invest 73:649–657.
11. Iozzo RV. 1994. Perlecan: a gem of a proteoglycan. Matrix Biol 14:203–208.
12. Noonan DM, Fulle A, Valente P, et al. 1991. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 266:22939–22947.
13. Kerever A, Schnack J, Vellinga D, et al. 2007. Novel extracellular matrix structures in the neural stem cell niche capture the neurogenic factor fibroblast growth factor 2 from the extracellular milieu. Stem Cells 25:2146–2157.
14. Whitelock JM, Melrose J, Iozzo RV. 2008. Diverse cell signaling events modulated by perlecan. Biochemistry 47:11174–11183.
15. Costell M, Gustafsson E, Aszodi A, et al. 1999. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 147:1109–1122.
16. Tsumaki N, Tanaka K, Arikawa-Hirasawa E, et al. 1999. Role of CDMP-1 in skeletal morphogenesis: promotion of mesenchymal cell recruitment and chondrocyte differentiation. J Cell Biol 144:161–173.
17. Xu Z, Ichikawa N, Kosaki K, et al. 2010. Perlecan deficiency causes muscle hypertrophy, a decrease in myostatin expression, and changes in muscle fiber composition. Matrix Biol 29:461–470.
18. Kerever A, Mercier F, Nonaka R, et al. 2014. Perlecan is required for FGF-2 signaling in the neural stem cell niche. Stem Cell Res 12:492–505.
19. Kaneko H, Ishijima M, Futami I, et al. 2013. Synovial perlecan is required for osteophyte formation in knee osteoarthritis. Matrix Biol 32:178–187.
20. Nonaka R, Iesaki T, de Vega S, et al. 2015. Perlecan deficiency causes endothelial dysfunction by reducing the expression of endothelial nitric oxide synthase. Physiol Rep 3:e122272.
21. Futami I, Ishijima M, Kaneko H, et al. 2012. Isolation and characterization of multipotential mesenchymal cells from the mouse synovium. PLoS ONE 7:e45517.
22. De Bari C, Dell'Accio F, Tylzanowski P, et al. 2001. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 44:1928–1942.
23. Shukunami C, Shigeno C, Atsumi T, et al. 1996. Chondrogenic differentiation of clonal mouse embryonic cell line ATDC5 in vitro: differentiation-dependent gene expression of parathyroid hormone (PTH)/PTH-related peptide receptor. J Cell Biol 133:457–468.
24. Cabral AR, Loya BL, Alarcon-Segovia D. 1989. Bone remodeling and osteophyte formation after remission of rheumatoid arthritis. J Rheumatol 16:1421–1427.
25. Hassell J, Yamada Y, Arikawa-Hirasawa E. 2002. Role of perlecan in skeletal development and diseases. Glycoconj J 19:263–267.
26. Knox SM, Whitelock JM. 2006. Perlecan: how does one molecule do so many things? Cell Mol Life Sci 63:2435–2445.
27. Arikawa-Hirasawa E, Wilcox WR, Le AH, et al. 2001. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat Genet 27:431–434.
28. Arikawa-Hirasawa E, Wilcox WR, Yamada Y. 2001. Dyssegmental dysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage development. Am J Med Genet 106:254–257.
29. Iwasaki M, Nakahara H, Nakata K, et al. 1995. Regulation of proliferation and osteochondrogenic differentiation of periosteum-derived cells by transforming growth factor-beta and basic fibroblast growth factor. J Bone Joint Surg Am 77:543–554.
30. Mierisch CM, Anderson PC, Balian G, et al. 2002. Treatment with insulin-like growth factor-1 increases chondrogenesis by periosteum in vitro. Connect Tissue Res 43:559–568.
31. Nakayama K, Tamura Y, Suzawa M, et al. 2003. Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J Bone Miner Res 18:827–835.
32. Okazaki K, Jingushi S, Ikenoue T, et al. 1999. Expression of insulin-like growth factor I messenger ribonucleic acid in developing osteophytes in murine experimental osteoarthritis and in rats inoculated with growth hormone-secreting tumor. Endocrinology 140:4821–4830.
33. Gomes RR Jr., Joshi SS, Farach-Carson MC, et al. 2006. Ribozyme-mediated perlecan knockdown impairs chondrogenic differentiation of C3H10T1/2 fibroblasts. Differentiation 74:53–63.
34. French MM, Gomes RR Jr., Timpl R, et al. 2002. Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I. J Bone Miner Res 17:48–55.
35. Smith SM, West LA, Govindraj P, et al. 2007. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. Matrix Biol 26:175–184.
36. Shao D, Lazar MA. 1997. Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 272:21473–21478.
37. Haakonsson AK, Stali Madsen M, Nielsen R, et al. 2013. Acute genome-wide effects of rosiglitazone on PPARgamma transcriptional networks in adipocytes. Mol Endocrinol 27:1536–1549.
38. Zhao QH, Wang SG, Liu SX, et al. 2013. PPARgamma forms a bridge between DNA methylation and histone acetylation at the C/EBPalpha gene promoter to regulate the balance between osteogenesis and adipogenesis of bone marrow stromal cells. FEBS J 280:5801–5814.
39. Matsumoto T, Kubo S, Meszaros LB, et al. 2008. The influence of sex on the chondrogenic potential of muscle-derived stem cells: implications for cartilage regeneration and repair. Arthritis Rheum 58:3809–3819.
40. Zanotti S, Kalajzic I, Aguila HL, et al. 2014. Sex and genetic factors determine osteoblastic differentiation potential of murine bone marrow stromal cells. PLoS ONE 9:e86757.